Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.creator | Vallejo-Blanco, A. (Adrián) | - |
| dc.creator | Erice, O. (Oihane) | - |
| dc.creator | Entrialgo-Cadierno, R. (Rodrigo) | - |
| dc.creator | Feliu, I. (Iker) | - |
| dc.creator | Guruceaga, E. (Elizabeth) | - |
| dc.creator | Perugorria, M.J. (María J.) | - |
| dc.creator | Olaizola, P. (Paula) | - |
| dc.creator | Muggli, A. (Alexandra) | - |
| dc.creator | Macaya, I. (Irati) | - |
| dc.creator | O’Dell, M. (Michael) | - |
| dc.creator | Ruiz-Fernandez-de-Cordoba, B. (Borja) | - |
| dc.creator | Ortiz-Espinosa, S. (Sergio) | - |
| dc.creator | Hezel, A.F. (Aram F.) | - |
| dc.creator | Arozarena, I. (Imanol) | - |
| dc.creator | Lecanda, F. (Fernando) | - |
| dc.creator | Avila, M.A. (Matías Antonio) | - |
| dc.creator | García-Fernández-de-Barrena, M. (Maite) | - |
| dc.creator | Evert, M. (Matthias) | - |
| dc.creator | Ponz-Sarvise, M. (Mariano) | - |
| dc.creator | Calvisi, D.F. (Diego F.) | - |
| dc.creator | Banales, J.M. (Jesús M.) | - |
| dc.creator | Vicent, S. (Silvestre) | - |
| dc.date.accessioned | 2022-04-05T11:08:55Z | - |
| dc.date.available | 2022-04-05T11:08:55Z | - |
| dc.date.issued | 2021 | - |
| dc.identifier.citation | Vallejo-Blanco, A. (Adrián); Erice, O. (Oihane); Entrialgo-Cadierno, R. (Rodrigo); et al. "FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted". Journal of Hepatology. 75 (2), 2021, 363 - 376 | es_ES |
| dc.identifier.issn | 0168-8278 | - |
| dc.identifier.uri | https://hdl.handle.net/10171/63351 | - |
| dc.description.abstract | Understanding the molecular mechanisms involved in cholangiocarcinoma (bile duct cancer) development and progression stands as a critical step for the development of novel therapies. Through an inter-species approach, this study provides evidence of the clinical and functional role of the transcription factor FOSL1 in cholangiocarcinoma. Moreover, we report that downstream effectors of FOSL1 are susceptible to pharmacological inhibition, thus providing new opportunities for therapeutic intervention. | es_ES |
| dc.description.sponsorship | A.V. was supported by ADA of the University of Navarra , Spain, O.E. by FSE ; MINECO ; FJCI-2017-34233 , Spain, R.E. by a donation from Mauge Burgos de la Iglesia’s family, Spain, and P. Olaizola by the Basque Government ( PRE_2016_1_0269 ), Basque Country, Spain. M.J.P. was funded by ISCIII [ FIS PI14; 00399 , PI17; 00022 ] cofinanced by “Fondo Europeo de Desarrollo Regional” (FEDER), Spain; Spanish Ministry of Economy and Competitiveness (MINECO: “Ramón y Cajal” Program RYC-2015-17755 ), Spain. M.A.A was funded by La Caixa Foundation , HEPACARE project , Spain, ISCIII FIS PI16/01126 cofinanced by “Fondo Europeo de Desarrollo Regional” (FEDER), Spain, and “Fundación Científica de la Asociación Española Contra el Cáncer’’ (AECC Scientific Foundation) Rare Cancers 2017, Spain. J.M.B. was funded by the Spanish Carlos III Health Institute (ISCIII) ( FIS PI15; 01132 , PI18; 01075 and Miguel Servet Program CON14; 00129 and CPII19; 00008 ), Spain, co-financed by “Fondo Europeo de Desarrollo Regional” (FEDER), Spain; “Euskadi RIS3” ( 2019222054 ) and BIOEF (Basque Foundation for Innovation and Health Research: EiTB Maratoia BIO15; CA; 016; BD), Basque Country , Spain; “Fundación Científica de la Asociación Española Contra el Cáncer” (AECC Scientific Foundation) Rare Cancers 2017, Spain. S.V. was supported by FEDER ; MINECO ( SAF2017-89944-R ), Spain, by the Government of Navarra-Health Research Department (58; 2018), Navarra, Spain, by La Caixa and Caja Navarra Foundation-CIMA agreement , Spain. None of the funding sources were involved in the decision to submit the article for publication. This article is based upon work from COST Action CA18122 European Cholangiocarcinoma Network, supported by COST (European Cooperation in Science and Technology). | es_ES |
| dc.language.iso | eng | es_ES |
| dc.publisher | Elsevier | es_ES |
| dc.rights | info:eu-repo/semantics/openAccess | es_ES |
| dc.subject | FOSL1 | es_ES |
| dc.subject | Cholangiocarcinoma | es_ES |
| dc.subject | Transcription factors | es_ES |
| dc.subject | Genetics | es_ES |
| dc.subject | Targeted therapies | es_ES |
| dc.title | FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted | es_ES |
| dc.type | info:eu-repo/semantics/article | es_ES |
| dc.description.note | This is an open access article under the CC BY-NC-ND license. | es_ES |
| dc.identifier.doi | 10.1016/j.jhep.2021.03.028 | - |
| dadun.citation.endingPage | 376 | es_ES |
| dadun.citation.number | 2 | es_ES |
| dadun.citation.publicationName | Journal of Hepatology | es_ES |
| dadun.citation.startingPage | 363 | es_ES |
| dadun.citation.volume | 75 | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.
